GlassScriptPhysician profile
Donald Halstead Moore
NPI 1235133562
$16,578.42
in general payments reported to CMS, 2019-2025
43 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,450 · 2020: $2,488 · 2021: $3,529 · 2022: $3,306 · 2023: $1,244 · 2024: $232 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,829.88 | 2019-2025 | Breztri, Fasenra, Farxiga |
| Novo Nordisk INC | $1,540.88 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,068.51 | 2020-2024 | |
| Amarin Pharma, INC. | $911.17 | 2019-2022 | |
| Amgen INC. | $881.95 | 2019-2022 | |
| Lilly USA, LLC | $838.45 | 2019-2023 | Jardiance, Trulicity, Mounjaro |
| Pfizer INC. | $826.63 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $821.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $717.78 | 2019-2023 | |
| Allergan, INC. | $666.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $543.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $506.86 | 2019-2025 | Nucala, Shingrix |
| Merck Sharp & Dohme LLC | $478.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $447.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.95 | 2019-2023 | Xifaxan |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.